Afluria Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recurring seasonal influenza outbreaks, public health vaccination policies, hospital-based immunization programs, rising infection-related hospitalizations, established vaccine manufacturing platforms.

The growth in the forecast period can be attributed to growth in preventive healthcare awareness, increasing vaccination coverage targets, expansion of retail pharmacy immunization, improved cold chain logistics, rising geriatric population. Major trends in the forecast period include rising demand for seasonal influenza vaccination, expansion of adult and pediatric immunization programs, increased focus on preventive healthcare, growth in government-supported vaccination campaigns, improved vaccine distribution infrastructure.

The increasing prevalence of influenza is expected to drive the growth of the Afluria market in the coming years. Influenza, commonly referred to as the flu, is a contagious respiratory illness caused by influenza viruses and can range from mild to severe, with symptoms such as fever, cough, sore throat, body aches, and fatigue. The rising prevalence of influenza is linked to factors including greater public awareness, higher incidence rates due to viral mutations, and growing demand for vaccination, particularly among high-risk groups such as older adults. Afluria is a vaccine used to prevent influenza by stimulating the immune system to generate antibodies against the flu virus. For example, in November 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, influenza positivity increased to 2.3% in week 41 as of October 16, 2024, up from 2% the previous week, with the highest positivity rate of 5.1% observed among children aged 5 to 14 years. Consequently, the rising prevalence of influenza is contributing to the growth of the Afluria market.

The expanding geriatric population is also expected to propel the growth of the Afluria market. The geriatric population typically includes individuals aged 65 years and older, who often face distinct health challenges associated with aging. This population segment is growing due to declining fertility rates and increasing life expectancy, leading to a higher proportion of elderly individuals within the overall population. Older adults are particularly susceptible to severe complications and higher mortality rates from influenza, increasing the need for effective vaccination options such as Afluria to protect this vulnerable group and reduce flu-related health risks. For instance, in July 2024, according to a report published by the House of Commons Library, a UK-based government agency, approximately 12.7 million people in the UK were aged 65 and over in 2022, representing 19% of the total population, and this figure is projected to rise to 22.1 million, or 27% of the population, by 2072. As a result, the growing geriatric population is supporting the expansion of the Afluria market.

Companies operating in the Afluria market are increasingly focusing on the development of innovative solutions, such as nano-sized particle-based vaccines, to improve vaccine effectiveness, stability, and targeted delivery. Nanoparticle-based vaccines utilize extremely small particles to enhance antigen delivery and strengthen immune responses. For example, in March 2024, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced the Cadiflu Tetra Vaccine, a next-generation quadrivalent influenza vaccine developed to prevent seasonal flu. This vaccine targets four influenza virus strains, including both A and B subtypes, and incorporates key viral proteins such as hemagglutinin, neuraminidase, and matrix 1 within a single formulation. This design provides broader protection, enhanced immunogenicity, and an improved safety profile compared with conventional influenza vaccines.

Major companies operating in the afluria market are CSL Seqirus.

North America was the largest region in the afluria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the afluria market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the afluria market by increasing costs related to vaccine raw materials, packaging components, and temperature-controlled logistics. These impacts have affected vaccine procurement budgets, particularly for public health programs and government suppliers in import-dependent regions. Hospital and retail pharmacy distribution channels in asia-pacific and africa are more exposed to tariff fluctuations. At the same time, tariffs have driven investments in local vaccine production, regional supply resilience, and expanded domestic immunization capacity.

The afluria market research report is one of a series of new reports that provides afluria market statistics, including afluria industry global market size, regional shares, competitors with a afluria market share, detailed afluria market segments, market trends and opportunities, and any further data you may need to thrive in the afluria industry. This afluria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Afluria is an inactivated influenza vaccine developed to protect against infections caused by specific strains of the influenza virus. It is approved for use in individuals aged six months and older and is administered by injection, helping to stimulate the immune system to produce protective antibodies. Annual vaccination is recommended to maintain effective protection against seasonal influenza outbreaks.

The main formulations of Afluria include pre-filled syringes and multi-dose vials. Pre-filled syringes provide a single-dose option that ensures accurate dosing and ease of administration and are widely used in outpatient clinics and pharmacies to support efficient immunization. These syringes also help reduce the risk of contamination. The primary clinical indication is influenza prevention, and the vaccine is distributed through hospitals and clinics, retail pharmacies, and government supply channels, with end users including pediatric, adult, and geriatric populations.

The afluria market consists of sales of afluria quadrivalent, and afluria trivalent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.